This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US
December 15 - 18, 2024
Marriott Marquis San DiegoLive In-Person Event: December 15 - 18, 2024

Bassil Dahiyat, PhD
President and CEO at Xencor


Bassil Dahiyat has been Xencor’s president and chief executive officer since the Company’s incorporation in August 1997. He has led the Company in creating a diverse portfolio of engineered antibodies and cytokines for the treatment of life-threatening and debilitating diseases, and has established alliances with leading biopharmaceutical companies that have resulted in three marketed drugs and the broad use of Xencor's XmAb engineering technology around the industry. Dr. Dahiyat has co-authored numerous scientific papers in the fields of protein design and drug delivery, is an inventor of over 30 U.S. and numerous foreign patents and has received scientific awards from the American Chemical Society, the Controlled Release Society, the Protein Society and Caltech. Dr. Dahiyat also serves as a member of the board of directors of Kodiak Sciences and Terray Therapeutics. He holds a Ph.D. in Chemistry from Caltech and B.S. and M.S.E. degrees in Biomedical Engineering from the Johns Hopkins University.

Agenda Sessions

  • Xencor’s 20 Year Journey in Antibody Therapeutic Development